Hypoglycemic and beta cell protective effects of andrographolide analogue for diabetes treatment
Open Access
- 16 July 2009
- journal article
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 7 (1) , 62
Abstract
Background: While all anti-diabetic agents can decrease blood glucose level directly or indirectly, few are able to protect and preserve both pancreatic beta cell mass and their insulin-secreting functions. Thus, there is an urgent need to find an agent or combination of agents that can lower blood glucose and preserve pancreatic beta cells at the same time. Herein, we report a dual-functional andrographolide-lipoic acid conjugate (AL-1). The anti-diabetic and beta cell protective activities of this novel andrographolide-lipoic acid conjugate were investigated.Methods: In alloxan-treated mice (a model of type 1 diabetes), drugs were administered orally once daily for 6 days post-alloxan treatment. Fasting blood glucose and serum insulin were determined. Pathologic and immunohistochemical analysis of pancreatic islets were performed. Translocation of glucose transporter subtype 4 in soleus muscle was detected by western blot. In RIN-m cellsin vitro, the effect of AL-1 on H2O2-induced damage and reactive oxidative species production stimulated by high glucose and glibenclamide were measured. Inhibition of nuclear factor kappa B (NF-κB) activation induced by IL-1β and IFN-γ was investigated.Results: In alloxan-induced diabetic mouse model, AL-1 lowered blood glucose, increased insulin and prevented loss of beta cells and their dysfunction, stimulated glucose transport protein subtype 4 (GLUT4) membrane translocation in soleus muscles. Pretreatment of RIN-m cells with AL-1 prevented H2O2-induced cellular damage, quenched glucose and glibenclamide-stimulated reactive oxidative species production, and inhibited cytokine-stimulated NF-κB activation.Conclusion: We have demonstrated that AL-1 had both hypoglycemic and beta cell protective effects which translated into antioxidant and NF-κB inhibitory activity. AL-1 is a potential new anti-diabetic agent.Keywords
This publication has 48 references indexed in Scilit:
- Synthesis and evaluation of antibacterial activities of andrographolide analoguesEuropean Journal of Medicinal Chemistry, 2009
- Evidence for a Role of Superoxide Generation in Glucose-Induced β-Cell Dysfunction In VivoDiabetes, 2007
- α-Lipoic Acid Prevents the Increase in Atherosclerosis Induced by Diabetes in Apolipoprotein E–Deficient Mice Fed High-Fat/Low-Cholesterol DietDiabetes, 2006
- Sulfonylurea as well as elevated glucose levels stimulate reactive oxygen species production in the pancreatic β-cell line, MIN6—a role of NAD(P)H oxidase in β-cellsBiochemical and Biophysical Research Communications, 2004
- Alpha-lipoic acid modulates NF-κB activity in human monocytic cells by direct interaction with DNAExperimental Gerontology, 2002
- Sustained Enhancement of Ca2+ Influx by Glibenclamide Induces Apoptosis in RINm5F CellsBiochemical and Biophysical Research Communications, 2000
- Suppression of Rat Neutrophil Reactive Oxygen Species Production and Adhesion by the Diterpenoid Lactone AndrographolidePlanta Medica, 2000
- HYPOTENSIVE ACTIVITY OF AQUEOUS EXTRACT OF ANDROGRAPHIS PANICULATA IN RATSClinical and Experimental Pharmacology and Physiology, 1996
- Glucose transporter levels in spontaneously obese (db/db) insulin-resistant mice.Journal of Clinical Investigation, 1990
- Functional beta cell regeneration in the islets of pancreas in alloxan induced diabetic rats by (−)-epicatechinLife Sciences, 1982